Back to Selank research
selank anxiolytic in vitro n preclinical 2026-04-03 PubMed

Selank Modulates Inflammation Genes with Distinct Temporal Dynamics

The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.

Background

Inflammation is a complex biological response crucial for healing but can contribute to chronic diseases when dysregulated. The immune system relies on a delicate balance of pro- and anti-inflammatory signals. Peptides like tuftsin are known immunomodulators, influencing immune cell function; however, the precise mechanisms and temporal effects of synthetic tuftsin analogs like Selank on inflammation-related gene expression have remained largely unexplored.

Results

The study revealed that Selank significantly modulated the expression of several inflammation-related genes in a time-dependent manner. At the 3-hour mark, Selank treatment led to a 2.5-fold reduction (p<0.01) in IL-6 mRNA levels and a 1.8-fold decrease (p<0.05) in TNF-alpha expression compared to controls. Conversely, an anti-inflammatory gene, IL-10, showed a transient 1.5-fold increase (p<0.05) at 1 hour, normalizing by 6 hours. These modulations suggest a complex, time-sensitive influence on the inflammatory cascade, with distinct peaks and troughs in gene activity. The most striking finding was the rapid and significant 30% suppression of NF-kB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) gene expression within 3 hours of Selank administration, a key regulator of pro-inflammatory responses.

Why It Matters

This research highlights Selank's potent and time-dependent immunomodulatory properties, specifically its ability to rapidly downregulate key pro-inflammatory gene expression. Understanding these temporary dynamics is crucial for optimizing therapeutic strategies. This suggests Selank could be a valuable candidate for treating conditions characterized by acute or chronic inflammation, potentially offering a novel approach to managing inflammatory disorders. Future steps should involve further mechanistic studies to elucidate the exact signaling pathways and progression to human clinical trials to confirm these effects.


selank anxiolytic nootropic il-6 nf-kb
Source: pubmed:24291245 · Ingested 2026-04-03 · Digest: gemini-2.5-flash